Judah Folkman

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
    Philip Hahnfeldt
    Dana Farber Cancer Institute and Department of Radiation Oncology, Harvard Medical School, Boston, MA, 02115, USA
    J Theor Biol 220:545-54. 2003
  2. ncbi request reprint Angiogenesis research: guidelines for translation to clinical application
    J Folkman
    Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Thromb Haemost 86:23-33. 2001
  3. ncbi request reprint Fundamental concepts of the angiogenic process
    Judah Folkman
    Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Curr Mol Med 3:643-51. 2003
  4. ncbi request reprint A novel anti-vascular therapy for cancer
    Judah Folkman
    Children s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Biol Ther 3:338-9. 2004
  5. ncbi request reprint Angiogenesis and apoptosis
    Judah Folkman
    Department of Surgery, Children s Hospital and Harvard Medical School, Hunnewell 103 300 Longwood Avenue, Boston, MA 02115, USA
    Semin Cancer Biol 13:159-67. 2003
  6. ncbi request reprint Angiogenesis and proteins of the hemostatic system
    J Folkman
    Department of Surgery, Children s Hospital and Harvard Medical School, Boston, MA, USA
    J Thromb Haemost 1:1681-2. 2003
  7. ncbi request reprint Looking for a good endothelial address
    Judah Folkman
    Department of Surgery, Children s Hospital and Harvard Medical School, Boston, MA, USA
    Cancer Cell 1:113-5. 2002
  8. pmc Platelets actively sequester angiogenesis regulators
    Giannoula Lakka Klement
    Children s Hospital, Boston, MA 02115, USA
    Blood 113:2835-42. 2009
  9. doi request reprint Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability
    Ofer Fainaru
    Vascular Biology Program, Children s Hospital Boston, Department of Surgery, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115, USA
    FASEB J 22:3728-35. 2008
  10. pmc PPARalpha deficiency in inflammatory cells suppresses tumor growth
    Arja Kaipainen
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 2:e260. 2007

Detail Information

Publications95

  1. ncbi request reprint Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
    Philip Hahnfeldt
    Dana Farber Cancer Institute and Department of Radiation Oncology, Harvard Medical School, Boston, MA, 02115, USA
    J Theor Biol 220:545-54. 2003
    ..This lends theoretical support to recent empirical studies showing that regularly spaced dosing schedules with no extended rest periods act more antiangiogenically, thereby delaying or avoiding the onset of acquired resistance...
  2. ncbi request reprint Angiogenesis research: guidelines for translation to clinical application
    J Folkman
    Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Thromb Haemost 86:23-33. 2001
    ..In the future, angiogenesis inhibitors may be added to chemotherapy or to radiotherapy, or to other modalities. Also, combinations of angiogenesis inhibitors may be administered together...
  3. ncbi request reprint Fundamental concepts of the angiogenic process
    Judah Folkman
    Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Curr Mol Med 3:643-51. 2003
    ..My goal is to provide a conceptual framework for those basic scientists or clinicians who may enter this rapidly expanding field. Each concept discussed here is accompanied by a few key references as a guide to the pertinent literature...
  4. ncbi request reprint A novel anti-vascular therapy for cancer
    Judah Folkman
    Children s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Biol Ther 3:338-9. 2004
  5. ncbi request reprint Angiogenesis and apoptosis
    Judah Folkman
    Department of Surgery, Children s Hospital and Harvard Medical School, Hunnewell 103 300 Longwood Avenue, Boston, MA 02115, USA
    Semin Cancer Biol 13:159-67. 2003
    ..Further improvement may be achieved by combining angiogenesis inhibitors with 'antiangiogenic chemotherapy'...
  6. ncbi request reprint Angiogenesis and proteins of the hemostatic system
    J Folkman
    Department of Surgery, Children s Hospital and Harvard Medical School, Boston, MA, USA
    J Thromb Haemost 1:1681-2. 2003
  7. ncbi request reprint Looking for a good endothelial address
    Judah Folkman
    Department of Surgery, Children s Hospital and Harvard Medical School, Boston, MA, USA
    Cancer Cell 1:113-5. 2002
    ..The first in vivo screening of a peptide library of the human vasculature opens new possibilities for inhibiting angiogenesis and tumor growth...
  8. pmc Platelets actively sequester angiogenesis regulators
    Giannoula Lakka Klement
    Children s Hospital, Boston, MA 02115, USA
    Blood 113:2835-42. 2009
    ....
  9. doi request reprint Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability
    Ofer Fainaru
    Vascular Biology Program, Children s Hospital Boston, Department of Surgery, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115, USA
    FASEB J 22:3728-35. 2008
    ..The potential of doxycyline as a therapeutic inhibitor of vascular hyperpermeability in human clinical conditions is promising and warrants further studies...
  10. pmc PPARalpha deficiency in inflammatory cells suppresses tumor growth
    Arja Kaipainen
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 2:e260. 2007
    ..These findings suggest that the absence of PPARalpha activity renders inflammatory infiltrates tumor suppressive and, thus, may provide a target for inhibiting tumor growth by modulating stromal processes, such as angiogenesis...
  11. pmc Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis
    Christian M Becker
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
    Am J Pathol 178:1782-91. 2011
    ....
  12. pmc Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
    Santosh Kesari
    Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, 44 Binney St, SW430D, Boston, MA 02115, USA
    Neuro Oncol 10:300-8. 2008
    ..07) and PFS (p=0.09). The addition of celecoxib and thalidomide to adjuvant temozolomide was well tolerated but did not meet the primary end point of improvement of 4-month PFS from study enrollment...
  13. pmc PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
    Dipak Panigrahy
    Vascular Biology Program, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:985-90. 2008
    ..Our results provide a mechanistic rationale for evaluating the clinical benefits of PPARalpha agonists in cancer treatment, alone and in combination with other therapies...
  14. doi request reprint Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib
    Carmen M Barnes
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
    Pediatr Res 71:168-78. 2012
    ..We investigated the use of dietary omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) in the treatment of neuroblastoma both as a sole agent and in combination with sunitinib, a broad-spectrum tyrosine kinase receptor inhibitor...
  15. ncbi request reprint Endothelial progenitor cells contribute to accelerated liver regeneration
    Paul Beaudry
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Pediatr Surg 42:1190-8. 2007
    ..These results suggest that CEP cells play a role in regulating liver regeneration and that VEGF treatment can mobilize CEP cells to accelerate this process...
  16. pmc Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance
    George N Naumov
    Children s Hospital, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, and Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Clin Cancer Res 15:3484-94. 2009
    ..EGFR TKI resistance is not completely understood and has been associated with certain EGFR and K-RAS mutations and MET amplification...
  17. pmc An orally delivered small-molecule formulation with antiangiogenic and anticancer activity
    Ofra Benny
    Vascular Biology Program and Department of Surgery, Children s Hospital Boston, Harvard Medical School, 1 Blackfan Circle, St Karp Research Building, Boston, Massachusetts 02215, USA
    Nat Biotechnol 26:799-807. 2008
    ..We show that Lodamin is an oral nontoxic antiangiogenic drug that can be chronically administered for cancer therapy or metastasis prevention...
  18. ncbi request reprint A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype
    George N Naumov
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, MA, USA
    J Natl Cancer Inst 98:316-25. 2006
    ..We previously demonstrated that human tumors contain tumor cell populations that are heterogeneous in angiogenic activity. Here, we separated angiogenic from nonangiogenic human tumor cell populations and compared their growth...
  19. doi request reprint Dendritic cells augment choroidal neovascularization
    Kei Nakai
    Department of Surgery, Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Invest Ophthalmol Vis Sci 49:3666-70. 2008
    ..The purpose of the present study was to investigate the role of DCs in the development of CNV...
  20. pmc A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy
    Christian M Becker
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115, USA
    Am J Pathol 168:2074-84. 2006
    ..This novel, noninvasive model of endometriosis provides a means to study early angiogenesis in vivo and to monitor endometriotic growth and the efficacy of systemic antiangiogenic therapy...
  21. ncbi request reprint Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model
    Christian M Becker
    Department of Surgery, Vascular Biology Program, Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Fertil Steril 85:71-7. 2006
    ..To determine the active peptide regions inside the angiogenesis inhibitor endostatin that can inhibit endothelial migration in vitro and also inhibit endometriosis in a mouse model...
  22. ncbi request reprint Endostatin inhibits the growth of endometriotic lesions but does not affect fertility
    Christian M Becker
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Fertil Steril 84:1144-55. 2005
    ..To determine whether endometriosis can be treated with the angiogenesis inhibitor endostatin and the effect of this treatment on fertility and reproduction...
  23. doi request reprint Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium
    Paul Beaudry
    Department of Vascular Biology, Boston Children s Hospital, Boston, Massachusetts, USA
    Mol Cancer Ther 7:418-24. 2008
    ..In conclusion, dual targeting of tumor cells, potentially through RET inhibition, and tumor vasculature with ZD6474 leads to potent antitumor effects. This approach merits further investigation for patients with neuroblastoma...
  24. doi request reprint Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy
    Tong Young Lee
    Vascular Biology Program, Department of Surgery, Children s Hospital Boston and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:1487-93. 2008
    ..Lack of these amino acids gives rise to a molecule that is devoid of zinc, resulting in no antitumor activity. Our goal was to develop a new version of endostatin that does not show such deficiency...
  25. pmc Dose-dependent response of FGF-2 for lymphangiogenesis
    Lynn K Chang
    Vascular Biology Program, Department of Surgery, Children s Hospital Boston, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:11658-63. 2004
    ..e., in the absence of angiogenesis, in the mouse cornea...
  26. ncbi request reprint A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity
    Robert M Tjin Tham Sjin
    Vascular Biology Program, Department of Surgery, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:3656-63. 2005
    ..This peptide contains three histidines that are responsible for zinc binding. Mutations of the zinc-binding histidines abolished its antitumor and antimigration activities, but not antipermeability properties...
  27. doi request reprint Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation
    Oszkar Szentirmai
    Department of Genetics, Harvard Institutes of Medicine and Harvard Medical School, and Department of Pediatrics, Children s Hospital, Boston, MA, USA
    J Neurosurg 108:979-88. 2008
    ....
  28. ncbi request reprint Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin
    Ronit Satchi-Fainaro
    Children s Hospital Boston and Harvard Medical School, Vascular Biology Program, Department of Surgery, 1 Blackfan Circle, Karp Family Research Laboratories, Floor 12, Boston, Massachusetts 02115, USA
    Cancer Cell 7:251-61. 2005
    ..This activity likely contributes to TNP-470's antiangiogenic effect and suggests that caplostatin can be used in the treatment of cancer and inflammation...
  29. pmc Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib
    Arin K Greene
    Department of Surgery, Children s Hospital and Harvard Medical School, Boston, MA, USA
    Ann Surg 242:140-6. 2005
    ..To determine the effects of COX-2 specific inhibitors on postoperative adhesion formation...
  30. pmc Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis
    Karen S Moulton
    Department of Surgery, Children s Hospital Medical Center and Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:4736-41. 2003
    ..Our findings demonstrate that late-stage inhibition of angiogenesis can interrupt this positive feedback cycle. Inhibition of plaque angiogenesis and the secondary reduction of macrophages may have beneficial effects on plaque stability...
  31. ncbi request reprint Urinary matrix metalloproteinases and their endogenous inhibitors predict hepatic regeneration after murine partial hepatectomy
    Arin K Greene
    Department of Surgery and the Vascular Biology Program, Children s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
    Transplantation 78:1139-44. 2004
    ..We therefore hypothesized that urinary MMPs and their endogenous tissue inhibitors of matrix metalloproteinases (TIMPs) might also provide important information regarding initiation and progression of liver regeneration...
  32. ncbi request reprint Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor
    Anat Norden-Zfoni
    Children s Hospital Boston, Boston, Massachusetts, USA
    Clin Cancer Res 13:2643-50. 2007
    ..In this study, we investigated potential blood-based biomarkers for SU11248 (sunitinib malate), a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors...
  33. ncbi request reprint Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity
    Paul Beaudry
    Children s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:3514-22. 2005
    ..We hypothesized that antiangiogenic agents may have differential effects on CEPs and mature CECs and that these changes may serve as a marker of biological activity...
  34. ncbi request reprint CDK2 translational down-regulation during endothelial senescence
    Deborah A Freedman
    Vascular Biology Program, Department of Surgery, Children s Hospital, 1 Blackfan Circle, Harvard University Medical School, Karp Family Research Laboratories, Floor 12, Boston, MA 02115, USA
    Exp Cell Res 307:118-30. 2005
    ..Understanding the mechanisms regulating endothelial senescence will be critical in determining the role of endothelial senescence in tumor growth...
  35. ncbi request reprint Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470
    Ronit Satchi-Fainaro
    Vascular Biology Program and Department of Surgery, Boston Children s Hospital and Harvard Medical School, 1 Blackfan Circle, New Research Building, Boston, Massachusetts 02115, USA
    Nat Med 10:255-61. 2004
    ..This new approach for targeting angiogenesis inhibitors specifically to the tumor vasculature may provide a new strategy for the rational design of cancer therapies...
  36. doi request reprint Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype
    Nava Almog
    Center of Cancer Systems Biology, Caritas St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02135, USA
    Cancer Res 69:836-44. 2009
    ..These data will be instrumental in identifying novel early cancer biomarkers and could provide a rationale for development of dormancy-promoting tumor therapy strategies...
  37. pmc Regional control of tumor growth
    Alexander Zaslavsky
    Vascular Biology Program and Department of Surgery, Children s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Mol Cancer Res 8:1198-206. 2010
    ..Finally, our studies suggest that upregulation of TSP-1 in tumor cells is one method to suppress the growth of tumors in the upper abdomen...
  38. pmc Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype
    Nava Almog
    Center of Cancer Systems Biology, Steward Research and Specialty Projects Corp, St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, Massachusetts, United States of America
    PLoS ONE 7:e44001. 2012
    ..This work suggests novel means to reverse the malignant tumor phenotype into an asymptomatic dormant state and may provide promising targets for early detection or prevention of cancer...
  39. pmc Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins
    Tong Young Lee
    Department of Surgery, Children s Hospital Boston and Harvard Medical School, MA, USA
    Blood 114:1987-98. 2009
    ..Together, our data suggest mitochondria as a novel target for antiangiogenic therapy and provide mechanistic insights to the antiangiogenic and antitumor effects of angiostatin...
  40. pmc Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice
    Oliver Kisker
    Division of Surgical Research, Children s Hospital, Boston, MA 02115, USA
    Neoplasia 5:32-40. 2003
    ..Taken together, these data suggest that DBP-maf is an antiangiogenic molecule that can act directly on endothelium as well as stimulate macrophages to attack both the endothelial and tumor cell compartment of a growing malignancy...
  41. ncbi request reprint Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies
    Jennifer J Marler
    Vascular Anomalies Center and Department ofSurgery, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
    Pediatrics 116:38-45. 2005
    ..We sought to determine whether these angiogenesis modulators are present in the urine and whether their expression is associated with the extent and clinical course of the vascular lesion...
  42. pmc Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage
    Janka Kisucka
    CBR Institute for Biomedical Research, Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:855-60. 2006
    ..The adhesion function of platelets, as mediated by GPIbalpha, significantly contributes to the process...
  43. ncbi request reprint Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis
    Ofer Fainaru
    Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, 300 Longwood Ave, Boston, MA 02115, USA
    FASEB J 22:522-9. 2008
    ..93+/-32 cells, P=0.02). Based on these findings, we suggest a novel role for DCs in supporting angiogenesis and promoting lesion growth both in endometriosis and in tumors...
  44. ncbi request reprint The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model
    Patrick J Javid
    Department of Surgery, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
    J Pediatr Surg 40:1446-53. 2005
    ..We therefore examined whether the route of lipid administration would affect the development of PN-associated liver injury in a previously established animal model of PN-induced hepatic steatosis...
  45. ncbi request reprint Role of vascular endothelial growth factor A in children with acquired airway stenosis
    Reza Rahbar
    Department of Otolaryngology and Communication Disorders, Children s Hospital Boston, 300 Longwood Ave, Boston, MA 02115, USA
    Ann Otol Rhinol Laryngol 116:430-5. 2007
    ..Vascular endothelial growth factor A (VEGF-A) is important in the angiogenic response for wound healing. This study investigated whether VEGF-A may play a role in the pathogenesis of acquired airway stenosis...
  46. ncbi request reprint Role of endogenous angiogenesis inhibitors in Down syndrome
    Sandra Ryeom
    Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Craniofac Surg 20:595-6. 2009
    ..The molecular regulation of angiogenesis is not yet fully understood; however, the Down syndrome population may give us insights toward novel therapies for controlling angiogenesis in disease...
  47. ncbi request reprint Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch
    George N Naumov
    Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
    Cell Cycle 5:1779-87. 2006
    ....
  48. doi request reprint Beta-35 is a transferrin-derived inhibitor of angiogenesis and tumor growth
    Gang Liang
    Vascular Biology Program, Department of Surgery, Children s Hospital, and Harvard Medical School, Boston, MA, USA
    Biochem Biophys Res Commun 409:562-6. 2011
    ..The recombinant protein of Beta-35 shows significant anti-tumor activity at a dose of 5mg/kg/day against human pancreatic cancer or melanoma implanted subcutaneously in SCID mice...
  49. doi request reprint Tumor-vascular interactions and tumor dormancy
    George N Naumov
    Department of Surgery, Harvard Medical School and Vascular Biology Program, Children s Hospital Boston, Boston, MA, USA
    APMIS 116:569-85. 2008
    ..We also review current experimental human tumor dormancy models which closely recapitulate clinically observed delay in tumor progress...
  50. doi request reprint Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy
    Amir Abdollahi
    Center of Cancer Systems Biology, Dept of Medicine, St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA
    Drug Resist Updat 13:16-28. 2010
    ....
  51. ncbi request reprint A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer
    Mark W Kieran
    Department of Pediatric Oncology, Dana Farber Cancer Institute, and Division of Pediatric Hematology Oncology, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Pediatr Hematol Oncol 27:573-81. 2005
    ....
  52. ncbi request reprint Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis
    Nava Almog
    Vascular Biology Program and Department of Surgery, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA
    FASEB J 20:947-9. 2006
    ....
  53. pmc Evidence by molecular profiling for a placental origin of infantile hemangioma
    Carmen M Barnes
    Vascular Biology Program and Department of Surgery, Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 102:19097-102. 2005
    ..Furthermore, it suggests that the unique self-limited growth of infantile hemangioma may, in fact, mirror the lifetime of placental endothelium...
  54. doi request reprint Correlation of 2-methoxyestradiol levels in cord blood and complications of prematurity
    Carmen M Barnes
    Department of Surgery, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatr Res 67:545-50. 2010
    ..In summary, fetal 2ME2 concentrations do not appear to affect neonatal outcome...
  55. ncbi request reprint Is angiogenesis an organizing principle in biology and medicine?
    Judah Folkman
    Children s Hospital Boston, Department of Surgery and Vascular Biology Program, Harvard Medical School, Karp Family Research Laboratories 12 129, Boston, MA 02115 5737, USA
    J Pediatr Surg 42:1-11. 2007
  56. pmc HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model
    Tong Young Lee
    Vascular Biology Program, Department of Surgery, Children s Hospital Boston and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:e9945. 2010
    ..We conclude that the above HPSG binding peptide (6a-P) is a potent inhibitor of angiogenesis-dependent diseases...
  57. doi request reprint Doxycycline inhibits vascular leakage and prevents ovarian hyperstimulation syndrome in a murine model
    Ofer Fainaru
    Department of Surgery, Vascular Biology Program, Children s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Fertil Steril 92:1701-5. 2009
    ..To determine whether doxycycline would inhibit the development of ovarian hyperstimulation syndrome (OHSS) in a murine model...
  58. ncbi request reprint Role of angiogenesis in tumor growth and metastasis
    Judah Folkman
    Departments of Surgery and Cell Biology, Harvard Medical School, Boston, MA, USA
    Semin Oncol 29:15-8. 2002
    ..Phase 1 clinical trials of endostatin and angiostatin are ongoing, and preliminary results show minimal toxicities...
  59. ncbi request reprint Platelet-associated PF-4 as a biomarker of early tumor growth
    David Cervi
    Children s Hospital Boston, Karp Family Research Laboratories, Boston, MA 02115, USA
    Blood 111:1201-7. 2008
    ..We conclude that platelet-associated PF-4, but not its plasma counterpart, may represent a potential biomarker of early tumor presence...
  60. ncbi request reprint Treatment of human pancreatic cancer in mice with angiogenic inhibitors
    Daniela Prox
    Division of Surgical Research, Children s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA
    World J Surg 27:405-11. 2003
    ..The observed tumor suppression may be due to increased tumor cell apoptosis as a result of capillary dropout. These studies show that after the angiogenic switch in a human tumor, there is residual production of angiogenesis inhibitors...
  61. ncbi request reprint Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertension
    Jacques I Benisty
    Vascular Biology Program, The Children s Hospital, Boston, MA, USA
    Chest 128:572S. 2005
  62. ncbi request reprint Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment
    Michael Fannon
    Department of Surgery, The Children s Hospital, 300 Longwood Ave, Boston, Massachusetts 02115, USA
    FASEB J 17:902-4. 2003
    ..This mechanism suggests a physiological process to control bioavailability of angiogenic growth factors in the cornea...
  63. ncbi request reprint Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action
    Judah Folkman
    Children s Hospital Harvard Medical School, Cambridge, MA, USA
    Exp Cell Res 312:594-607. 2006
    ....
  64. ncbi request reprint Angiogenesis: an organizing principle for drug discovery?
    Judah Folkman
    Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA
    Nat Rev Drug Discov 6:273-86. 2007
    ....
  65. pmc Stem cell therapies benefit Alport syndrome
    Valerie LeBleu
    Division of Matrix Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    J Am Soc Nephrol 20:2359-70. 2009
    ..These data provide further support for testing cell-based therapies for Alport syndrome...
  66. pmc Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients
    Michael Retsky
    Department of Surgical Research, Children s Hospital and Harvard Medical School, Boston, MA, USA
    Breast Cancer Res 6:R372-4. 2004
    ..We could imagine that it also plays a role in adjuvant chemotherapy effectiveness since, perhaps not coincidentally, this is most beneficial for premenopausal node-positive patients...
  67. ncbi request reprint Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring
    Donald M McDonald
    University of California at San Francisco, San Francisco, CA, USA
    J Immunother 27:161-75. 2004
    ..The third addressed the translation to the clinic and monitoring of antiangiogenic activity of agents in patients and novel trial designs. What follows is a summary of the discussions and findings of each session...
  68. ncbi request reprint Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily
    Joseph P Eder
    Division of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 20:3772-84. 2002
    ..To perform a phase I trial of recombinant human endostatin (rhEndostatin; EntreMed, Rockville, MD) given as a daily 20-minute intravenous (IV) injection in adult patients with refractory solid tumors...
  69. pmc Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates
    Fiona H Blackhall
    Department of Medical Oncology, University of Manchester, Cancer Research UK, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Biochem J 375:131-9. 2003
    ..The results indicate that 6-O-sulphates play a dominant role in site selectivity and 2-O-sulphates are not strictly essential...
  70. ncbi request reprint Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells
    Gunter Schuch
    Department of Urology, Children s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 63:8345-50. 2003
    ..We propose that endothelial progenitor cells are a novel target for endostatin and suggest that the relative numbers of CECs can serve as a surrogate marker for the biological activity of antiangiogenic treatment...
  71. pmc Endothelial-directed hepatic regeneration after partial hepatectomy
    Arin K Greene
    Department of Surgery, Children s Hospital, Harvard Medical School, 300 Longwood Avenue, Hunnewell 103, Boston, MA 02115, USA
    Ann Surg 237:530-5. 2003
    ..To determine the role of the microvascular endothelium in the regulation of regenerating liver mass after partial hepatectomy...
  72. ncbi request reprint Angiogenesis inhibitors: a new class of drugs
    Judah Folkman
    Harvard Medical School, Children s Hospital Boston, Massachusetts 02115 USA
    Cancer Biol Ther 2:S127-33. 2003
    ..Some of the more significant guidelines of antiangiogenic therapy are assembled in this chapter, and their scientific basis is discussed...
  73. ncbi request reprint Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us
    Lynn Hlatky
    Dana Farber Cancer Institute and the Department of Radiation Oncology, Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 94:883-93. 2002
  74. ncbi request reprint A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells
    Anthony S Don
    Centre for Vascular Research, University of New South Wales and Department of Haematology, Prince of Wales Hospital, Sydney, Australia
    Cancer Cell 3:497-509. 2003
    ..GSAO inhibited angiogenesis in the chick chorioallantoic membrane and in solid tumors in mice. Consequently, GSAO inhibited tumor growth in mice with no apparent toxicity at efficacious doses...
  75. ncbi request reprint Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases
    Jennifer J Marler
    Department of Surgery, Children s Hospital, Boston, Massachusetts 02115, USA
    Pediatrics 109:E37. 2002
    ....
  76. ncbi request reprint Judah Folkman
    Karen Birmingham
    Nat Med 8:1052. 2002
  77. ncbi request reprint Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension
    Jacques I Benisty
    Karp Family Research Building Room 11213 1, Children s Hospital Boston, 300 Longwood Avenue, Boston, MA 02115 5737, USA
    Chest 126:1255-61. 2004
    ..We hypothesized that angiogenic growth factors may have a role in the molecular mechanisms underlying this cellular proliferation...
  78. pmc A review of Judah Folkman's remarkable achievements in biomedicine
    Yihai Cao
    Department of Microbiology and Tumor and Cell Biology, Karolinska Institute, 171 77 Stockholm, Sweden
    Proc Natl Acad Sci U S A 105:13203-5. 2008
  79. ncbi request reprint Endogenous angiogenesis inhibitors
    Judah Folkman
    Departments of Surgery, Children s Hospital and Harvard Medical School and Vascular Biology Program, Children s Hospital, Boston, Massachusetts 02115, USA
    APMIS 112:496-507. 2004
    ....
  80. ncbi request reprint An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: clipped beta2-glycoprotein-I
    Wolf Dietrich C Beecken
    Department of Urology, JW Goethe University, Frankfurt am Main, Germany
    Ann Surg Oncol 13:1241-51. 2006
    ..It has been postulated that primary tumors release angiogenesis-blocking proteins which suppress distant metastases. We have identified an endogenous protein which might be responsible for tumor dormancy...
  81. ncbi request reprint Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice
    Lyudmila G Burdelya
    Department of Molecular Genetics, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cancer Res 66:9356-61. 2006
    ..Thus, reversible pharmacologic suppression of p53 may be a viable approach to improving anticancer treatment via an enhanced antiangiogenic effect of chemotherapy and radiotherapy...
  82. pmc Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma
    Louis Chesler
    Department of Pediatrics, Neurology, University of California San Francisco Medical School, San Francisco, California 94143, USA
    Cancer Res 67:9435-42. 2007
    ....
  83. pmc 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis
    Christian M Becker
    Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Womens Centre Headington, University of Oxford, Oxford, OX3 9DU, UK
    Am J Pathol 172:534-44. 2008
    ....
  84. ncbi request reprint Judah Folkman
    Hellmut G Augustin
    DKFZ and University of Heidelberg
    Thromb Haemost 99:250. 2008
  85. doi request reprint Retrospective: Judah Folkman (1933-2008)
    Douglas Hanahan
    Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA
    Science 319:1055. 2008
  86. ncbi request reprint Antiangiogenic activity of a matrix protein
    Judah Folkman
    Harvard Medical School Children s Hospital Hunnelwell 103 300 Longwood Ave Boston, Massachusetts 02115 5737, USA
    Cancer Biol Ther 2:53-4. 2003
  87. doi request reprint Judah Folkman leaves expanding legacy
    Vicki Brower
    J Natl Cancer Inst 100:380-1. 2008
  88. doi request reprint The placenta theory and the origin of infantile hemangioma
    Carmen M Barnes
    Vascular Biology Program and Department of Surgery, Children s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lymphat Res Biol 5:245-55. 2007
    ..Special emphasis will be placed on placental vasculogenesis and the presence and transit of placental progenitor cells during gestation...
  89. doi request reprint Angiogenesis and the progress of vascular and tumor biology: a tribute to Judah Folkman
    Maria Benedetta Donati
    Thromb Haemost 99:647-50. 2008
  90. pmc PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
    Dipak Panigrahy
    Surgical Research Laboratory, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 110:923-32. 2002
    ..These results suggest that PPARgamma ligands may be useful in treating angiogenic diseases such as cancer by inhibiting angiogenesis...
  91. ncbi request reprint [The passing of a concepts agitator]
    Christian Jacques Larsen
    Bull Cancer 95:263-4. 2008
  92. pmc Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding
    Steven J Fishman
    Department of Surgery, Children s Hospital Boston and Harvard Medical School, Boston, MA 02115, USA
    Ann Surg 241:523-8. 2005
    ..We report the largest clinical experience to date of surgically treated patients with blue rubber bleb nevus syndrome (BRBNS)...
  93. ncbi request reprint Clinical translation of angiogenesis inhibitors
    Robert Kerbel
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, S 218, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Nat Rev Cancer 2:727-39. 2002
    ..What are the most common questions that clinicians ask as they begin to test angiogenesis inhibitors in cancer clinical trials?..
  94. ncbi request reprint Angiogenesis
    Judah Folkman
    Vascular Biology Program, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115 5737, USA
    Annu Rev Med 57:1-18. 2006
    ..Several types of angiogenesis inhibitors reveal a biphasic, U-shaped curve of efficacy. "Antiangiogenic chemotherapy" is a novel approach to the treatment of drug resistance...